Article
Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.
Nature communications - 9 Dec 2025
Magbanua Mark Jesus M, Manon Nayelis A, Wolf Denise M, Rivero-Hinojosa Samuel, Ahmed Ziad, Sayaman Rosalyn W, Tin Antony, Renner Derrick, Kalashnikova Ekaterina, Brown-Swigart Lamorna, Hirst Gillian L, Yau Christina, Li Wen, Isaacs Claudine, Shatsky Rebecca A, Clark Amy S, Zimmer Alexandra, Delson Amy L, Rodriguez Angel, Liu Minetta C, Pohlmann Paula R, Esserman Laura J, Rugo Hope S, DeMichele Angela, van 't Veer Laura
Abstract excerpt
Early-stage breast cancers resistant to neoadjuvant therapy (NAT), characterized by high residual cancer burden (RCB) after treatment, have an increased risk of metastatic recurrence. Here, we show that circulating tumor DNA (ctDNA) detected using a tumor-informed test (1) can improve risk stratification of patients with NAT-resistant tumors (RCB-II/RCB-III) and (2) predict response to NAT. Stratification using...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.